Research ArticleExperimental Studies
Open Access

Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis

HONG-YI CHIU, SHIH-CHANG TSAI, FUU-JEN TSAI, YU-HSIANG LO, CHING-CHANG CHENG, TING-YUAN LIU, SYUN-RONG JHAN, JAI-SING YANG and YU-JEN CHIU
In Vivo May 2023, 37 (3) 1037-1046; DOI: https://doi.org/10.21873/invivo.13178

Abstract

Background/Aim: Non-alcoholic fatty liver disease is a major cause of liver-related morbidity and mortality. Metformin is a widely used medication and may have additional benefits beyond glycemic control. Liraglutide, a novel treatment for diabetes and obesity, also has beneficial effects on non-alcoholic steatohepatitis (NASH). Metformin and liraglutide have both benefited NASH treatment. However, no study has reported the effects of combination therapy with liraglutide and metformin on NASH. Materials and Methods: We investigated the in vivo effects of metformin and liraglutide on NASH in a methionine/choline-deficient (MCD) diet-fed C57BL/6JNarl mouse model. Serum triglyceride, alanine aminotransferase and alanine aminotransferase levels were documented. Histological analysis was performed according to the NASH activity grade. Results: After treatment with liraglutide and metformin, body weight loss improved, and the liver/body weight ratio decreased. The metabolic effects and liver injury improved. Liraglutide and metformin alleviated MCD-induced hepatic steatosis and injury. Histological analysis revealed that NASH activity was reduced. Conclusion: Our results provide evidence for the anti-NASH activity of liraglutide in combination with metformin. Liraglutide with metformin may offer the potential for a disease-modifying intervention for NASH.

Key Words:

Non-alcoholic fatty liver disease (NAFLD) is emerging as a major cause of liver-related morbidity and mortality, with a global prevalence of 25.24% (1). It is linked to obesity, insulin resistance and metabolic syndrome, and its appearance ranges from fat accumulation to advanced fibrosis and cirrhosis (2). It is now widely recognized that NAFLD represents a continuum of liver damage, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis (3, 4). The risk of developing NASH and fibrosis is significantly higher in patients with metabolic comorbidities, such as obesity, diabetes and dyslipidemia (5). While current treatment options focus on lifestyle modifications and management of associated comorbidities, ongoing research is exploring the potential of pharmacological therapies. Recent clinical trials have explored the efficacy of various agents for NASH treatment, including insulin sensitizers, lipid-lowering drugs, and agents targeting inflammation and fibrosis (6-8). However, there is still a lack of consensus regarding the most effective therapeutic approach, and further research is needed to establish the safety and long-term efficacy of these agents (7).

Liraglutide is used to treat type 2 diabetes mellitus (T2DM) and obesity (9, 10). It is a glucagon-like peptide-1 (GLP1) receptor agonist that increases insulin secretion, reduces glucagon secretion and slows gastric emptying (11). This medication has been extensively studied in recent years, and several new findings have emerged regarding its safety and efficacy [reviewed in (12)]. It is recommended as a first-line treatment option by expert organizations such as the American Diabetes Association and European Association for the Study of Diabetes (12, 13). Recent studies have shown that liraglutide may also have a beneficial effect on NASH (14-16). A randomized controlled trial published in The Lancet in 2019 reported that liraglutide was associated with a significant reduction in liver fat content and liver stiffness compared with placebo in patients with NAFLD (16). These studies also found that liraglutide improved insulin sensitivity and lipid metabolism (17-20).

Metformin has widely been used for the management of T2DM for decades (21). Recent studies suggest that metformin may have additional benefits beyond glycemic control (21, 22) and may also be effective in treating NAFLD (23-25). A systematic review and meta-analysis reported that metformin was associated with a significant reduction in liver fat content in patients with NASH (26, 27). Moreover, studies reported that metformin is associated with improvements in liver function and insulin sensitivity in patients with NASH (28-32). These findings suggest that metformin may be a promising treatment option for patients with NASH, particularly for those with T2DM.

Metformin and liraglutide have shed light on NASH treatment. However, to the best of our knowledge, no study has reported the effects of combination therapy with liraglutide and metformin on NASH. In this study, we used a methionine/choline-deficient (MCD) diet-fed C57BL/6JNarl mouse model to study the combined effects of liraglutide and metformin on NASH (33, 34).

Materials and Methods

Chemicals and materials. Liraglutide was purchased from Novo Nordisk, Denmark. Metformin was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The basic diet (Prolab®,

RMH2500, 5P14) was purchased from LabDiet, Inc. (St. Louis, MO, USA) and an MCD diet (A02082002B) was purchased from Research Diet Inc. (New Brunswick, NJ, USA). The nutritional composition of the basic and MCD diets are presented in Table I. Table II shows the amino acid composition of the MCD diet.

View this table:
Table I.

Nutritional composition of standard diet and methionine and choline-deficient diet (MCD).

View this table:
Table II.

Composition of amino acids in the methionine/choline deficient diet (MCD).

Animal studies. Six-week-old male C57BL/6JNarl mice were purchased from the National Laboratory Animal Center (Taipei City, Taiwan, ROC). They were housed in wire-mesh cages (39×26×21 cm) at 60% humidity with a 12 h-12 h light/dark cycle (light phase was 8:00 a.m. to 8:00 p.m.). The temperature was maintained at 23±1°C. The Institutional Animal Care and Use Committee of the China Medical University approved the experimental protocol (No. CMUIACUC-2020-013). For the 9-week study period, mice were randomly divided into five experimental groups.

  1. Normal control group fed a standard diet for all 9 weeks (n=3).

  2. NASH control group fed an MCD diet for all 9 weeks (n=3).

  3. Liraglutide-treated group fed an MCD diet for 4 weeks then MCD combined with treatment with 0.5 mg/kg liraglutide (subcutaneous, daily, 5 times a week) for 5 more weeks (n=3).

  4. Metformin-treated group fed an MCD diet for 4 weeks then MCD combined with treatment with 100 mg/kg metformin (oral administration, daily, 5 times a week) for 5 more weeks (n=3).

  5. Combination-treated group fed an MCD diet for 4 weeks then MCD combined with treatment with liraglutide and metformin as above for 5 more weeks (n=3).

Animals were monitored for the study period, with measurement of body weight at intervals; a weight loss of over 25% fulfilled the criterion for euthanasia. At the end of the 9 weeks, animals were sacrificed and serum triglycerides (TG), alanine aminotransferase (ALT) and alanine aminotransferase (AST) levels were documented. Livers were excised and histological analysis was performed.

Analysis of serum TG, ALT and AST levels. Serum ALT, AST and TG levels were determined using a Fujifilm Dri-Chem NX-500 automated clinical chemistry analyzer. All consumables used for testing (Fuji Dri-Chem Slide GOT/AST-P III, #3150; GPT/ALT-P III, #3250; TG-P III, #1650) were manufactured by Fujifilm (Tokyo, Japan), and each batch of consumables was calibrated using the original quality control card before use.

Histological analysis. Liver tissues from the C57BL/6JNarl mice were fixed in 10% neutral formalin, dehydrated, paraffin-embedded and cut into 5 mm-thick sections for hematoxylin-eosin staining. The NASH activity grade was evaluated according to the World Gastroenterology Organisation (35).

Statistical analysis. The results are expressed as the mean±standard error of the mean (n=3) and significance among multiple experimental groups was estimated using one-way analysis of variance (ANOVA), followed by Dunnett’s test or Tukey’s post hoc test using SPSS 16.0 software (SPSS, Inc., IBM, Armonk, NY, USA). A value of p<0.05 indicated statistical significance.

Results

Liraglutide and metformin ameliorated body weight loss and reduced the liver/body weight ratio. After 4 weeks of standard or MCD diet, the mice were treated with metformin, liraglutide, or liraglutide plus metformin for another 5 weeks. Figure 1 shows that MCD control mice weighed 33.3% less (17.10±0.97 g) than age- and sex-matched normal control mice (27.67±0.67 g). Initially, the MCD control mice lost more weight than those of the normal control group. After 2 weeks on the MCD diet, these mice had lost 25% of their body mass/week, 3% in week 3 and 2% thereafter. There was no significant increase in body weight with metformin, compared to MCD control mice; however, there was a significant increase in body weight in mice treated with liraglutide or metformin plus liraglutide, compared to MCD control mice. Figure 2 shows liraglutide led to a significant reduction in the liver/body weight ratio in the liraglutide-treated and liraglutide plus metformin-treated groups; however, the liver/body weight ratio under treatment with metformin did not significantly differ from that under MCD alone.

Figure 1.
Figure 1.

Body weight of C57BL/6JNarl mice in the five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. The results are expressed as the mean±standard error of the mean (n=3). Means with different letters at 35 days are significantly different at p<0.05.

Figure 2.
Figure 2.

Liver/body weight ratio of C57BL/6JNarl mice in five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. The results are expressed as the mean±standard error of the mean (n=3). Means with different letters are significantly different at p<0.05.

Liraglutide and metformin alleviated metabolic effects and liver injury in mice on an MCD diet. TGs are affected by metformin (36). Figure 3 shows serum TG levels in MCD control mice were significantly increased compared to normal controls. Metformin treatment alone did not significantly affect the TG level. Treatment with liraglutide, alone and combined with metformin, did significantly reduce the serum TG level compared to MCD control mice.

Figure 3.
Figure 3.

Serum triglyceride levels of C57BL/6JNarl mice in five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. The results are expressed as the mean±standard error of the mean (SEM) (n=3). Means with different letters are significantly different at p<0.05.

The enzyme AST is found in the liver, heart, skeletal muscle and other tissues in the body. An elevated AST level may indicate liver damage or other underlying medical conditions (19, 37). Liraglutide significantly reduces the level of ALT, an enzyme produced in liver cells that leaks into the bloodstream when cells are damaged (19, 37). Liver function in non-diabetic NAFLD can be improved by metformin therapy (26, 27). The ALT and AST levels were, therefore, examined in the study groups. MCD control mice had a significantly higher serum AST level, more than double that of normal control mice. Similarly, the serum ALT level in MCD control mice was significantly higher, by over 5-fold, than in normal control mice. Our results showed that a reduction in AST and ALT levels was observed in the liraglutide-only and metformin plus liraglutide groups compared to MCD control mice (Figure 4). Our results suggest that the combination of metformin and liraglutide may have positive effects on liver enzymes and liver function in mice with MCD-induced hepatic steatosis.

Figure 4.
Figure 4.

Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of C57BL/6JNarl mice in five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. The results are expressed as the mean±standard error of the mean (n=3). Means with different letters are significantly different at p<0.05.

Liraglutide and metformin alleviate MCD-induced hepatic steatosis and injury. Several animal studies have demonstrated the effectiveness of liraglutide or metformin in preventing hepatic steatosis and injury in animals of NAFLD [reviewed in (38)]. We further investigated the effect of this combination on MCD-induced hepatic steatosis. The hematoxylin and eosin staining results in Figure 5 and NASH activity grade in Table III demonstrate that liraglutide and metformin plus liraglutide attenuated MCD-induced hepatocyte steatosis, inflammation and ballooning. Our results suggest that the combination of metformin and liraglutide may have positive effects on hepatocyte steatosis and injury.

Figure 5.
Figure 5.

Hematoxylin-eosin staining in liver tissue of C57BL/6JNarl mice in five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. The results showed that liraglutide alone and in combination with metformin attenuated MCD-induced hepatocyte steatosis, inflammation and ballooning.

View this table:
Table III.

The grade of non-alcoholic steatohepatitis (NASH) (35) of liver from C57BL/6JNarl mice in five treatment groups. After 4 weeks of standard (control) or methionine/choline-deficient (MCD) diet, the mice were treated with 100 mg/kg metformin, 0.5 mg/kg liraglutide, or liraglutide plus metformin for another 5 weeks. Means with different letters are significantly different at p<0.05.

Discussion

NASH, an NAFLD, is a metabolic steatohepatitis syndrome with progressive pathological changes (39, 40). However, then are currently no U.S. Food and Drug Administration-approved therapy agents for NASH or related liver diseases (39). Because T2DM is associated with an increased risk of NASH (41, 42), many research groups have focused on liraglutide and metformin (T2DM therapy agents) for anti-NASH activity (43-47). Early studies showed that liraglutide reduced hepatic steatosis and insulin resistance in in vitro (48-51) and in vivo models (48, 49, 52, 53). The results of a phase II multicenter clinical trial (ClinicalTrials.gov-NCT01237119) showed that 39% of patients who received liraglutide had resolution of definite NASH compared with 9% of such patients in the placebo group (relative risk=4.3, 95% confidence interval=1.0-17.7; p=0.019) and suggested that liraglutide is a safe agent and leads to histological resolution of NASH (16). In this study, we focused on the anti-NASH activity of liraglutide and metformin in C57BL/6J mice fed an MCD diet. The MCD diet-fed C57BL/6J mouse model is a typical and representative nutritional NASH model (54, 55). The MCD diet fed to C57BL/6J mice for 4 weeks caused body weight loss, an increase in liver to body weight ratio, and increased serum TG, ALT and AST levels (56-58). Our results demonstrate that liraglutide significantly improved body weight loss (Figure 1), reduced the liver to body weight ratio (Figure 2), and reduced serum TG (Figure 3) and ALT and AST levels (Figure 4), as well as ameliorating hepatic steatosis and liver injury (Figure 5 and Table III). To the best of our knowledge, this is the first study to report that metformin plus liraglutide alleviates MCD-induced hepatic steatosis in this model.

Liraglutide is a GLP1 receptor agonist (59). In the pancreas, brain and adipose tissue, the mechanism of action of liraglutide, similar to physiological GLP1, for anti-diabetic effect is via controlling food intake, energy absorption and glucose-dependent insulin secretion (38). Liraglutide improves the histological features of NASH, including hepatocyte steatosis, inflammation and ballooning, but has no effect on fibrosis (38). In vitro and in vivo studies have demonstrated that liraglutide decreases de novo lipogenesis, increases fatty acid oxidation and reduces steatosis in human hepatocytes (60-62). Our results suggest that liraglutide improves anti-NASH activity by improving hepatic and adipose insulin sensitivity and reducing hepatic de novo lipogenesis. Metformin, a biguanide glucose-lowering agent, is a first-line therapy for T2DM (22). The mechanism of action of metformin for anti-diabetic effects are as follows: reducing hepatic gluconeogenesis and then reducing glucose production from the liver; reducing intestinal glucose absorption; reducing total cholesterol, low-density lipoprotein, or TG levels; activating AMP-activated protein kinase and regulating energy homeostasis such as lipid and glucose metabolism; reducing cholesterol biosynthesis; inhibiting mitochondrial complex I, preventing hepatic glucose production and increasing glucose utilization; increasing glucose uptake in the periphery; increasing muscle gluconeogenesis; promoting fatty acid oxidation; and improving insulin resistance (22, 63, 64). NAFLD-related studies demonstrated that metformin reduces fat accumulation in the liver and alleviates lipid peroxidation (27, 65-67). Li et al. demonstrated that metformin alleviated hepatocyte inflammation through signal transducer and activator of transcription 3-mediated autophagy (68). Autophagy is a double-edged sword for cell survival and death (69), providing nutrients to maintain cellular energy during fasting and removing damaged organelles, lipids and misfolded proteins in T2DM (69). Dan Zhang et al. demonstrated that metformin improved hepatic steatosis and insulin resistance, promoting transcription factor EB (TFEB)-dependent autophagy processes in a high-fat diet-induced model of NAFLD (70); it has been demonstrated that liraglutide improves hepatic steatosis, with similar effects in the same model (50). Our results suggest that liraglutide significantly improved hepatic steatosis and liver injury. Literature revealed that metformin enhanced anti-NASH activity possibly through promoting TFEB-dependent autophagy processes. In the future, we will test this hypothesis using next-generation sequencing and TFEB activity analysis (71).

In conclusion, our results provide evidence for the anti-NASH activity of liraglutide in combination with metformin. Liraglutide with metformin may offer a potential disease-modifying intervention for NASH.

Acknowledgements

The Authors wish to acknowledge the work of Mr Yung-Shuan Chang (Bio-Cando Ltd. Taiwan) for his excellent technical and equipment support in this study.

This study was supported by a project (grant no. TCRD109-63) from the Hualien Tzu Chi Hospital, Taiwan. This work was also supported in part by projects DMR-112-135 from China Medical University Hospital, Taiwan; V111B-040 from Taipei Veterans General Hospital, Taiwan; and MOST 111-2314-B-075 -083 -MY2 from the Ministry of Science and Technology, Taiwan.

Footnotes

  • Authors’ Contributions

    HY Chiu, JS Yang, FJ Tsai and YJ Chiu conceived and designed the experiments. SC Tsai, YH Lo and SR Jhan performed the experiments. CC Cheng, TY Liu and JS Yang analyzed the data. HY Chiu, SC Tsai, CC Cheng and JS Yang wrote and modified the article. All Authors read and approved the final article.

  • Conflicts of Interest

    The Authors declared no potential conflicts of interest with respect to the research, authorship and publication of this article.

  • Received March 6, 2023.
  • Revision received March 27, 2023.
  • Accepted March 29, 2023.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Chen G,
    2. Ni Y,
    3. Nagata N,
    4. Xu L and
    5. Ota T
    : Micronutrient antioxidants and nonalcoholic fatty liver disease. Int J Mol Sci 17(9): 1379, 2016. PMID: 27563875. DOI: 10.3390/ijms17091379
    OpenUrlCrossRefPubMed
  2. ↵
    1. Malnick SDH,
    2. Alin P,
    3. Somin M and
    4. Neuman MG
    : Fatty liver disease-alcoholic and non-alcoholic: similar but different. Int J Mol Sci 23(24): 16226, 2022. PMID: 36555867. DOI: 10.3390/ijms232416226
    OpenUrlCrossRefPubMed
  3. ↵
    1. Mahmoudi A,
    2. Jamialahmadi T,
    3. Johnston TP and
    4. Sahebkar A
    : Impact of fenofibrate on NAFLD/NASH: A genetic perspective. Drug Discov Today 27(8): 2363-2372, 2022. PMID: 35569762. DOI: 10.1016/j.drudis.2022.05.007
    OpenUrlCrossRefPubMed
  4. ↵
    1. Martel C,
    2. Esposti DD,
    3. Bouchet A,
    4. Brenner C and
    5. Lemoine A
    : Non-alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 13(5): 726-735, 2012. PMID: 22122481. DOI: 10.2174/138920112799857558
    OpenUrlCrossRefPubMed
  5. ↵
    1. Portillo-Sanchez P and
    2. Cusi K
    : Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol 2: 9, 2016. PMID: 28702244. DOI: 10.1186/s40842-016-0027-7
    OpenUrlCrossRefPubMed
  6. ↵
    1. Yang Z,
    2. Tian R,
    3. Zhang XJ,
    4. Cai J,
    5. She ZG and
    6. Li H
    : Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med 9: 1120085, 2023. PMID: 36712249. DOI: 10.3389/fcvm.2022.1120085
    OpenUrlCrossRefPubMed
  7. ↵
    1. Harvey BE
    : NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin 43(5): 1210-1214, 2022. PMID: 35110697. DOI: 10.1038/s41401-021-00832-z
    OpenUrlCrossRefPubMed
  8. ↵
    1. Oseini AM and
    2. Sanyal AJ
    : Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 37 Suppl 1(Suppl 1): 97-103, 2017. PMID: 28052626. DOI: 10.1111/liv.13302
    OpenUrlCrossRefPubMed
  9. ↵
    1. Perez-Montes DE Oca A,
    2. Pellitero S and
    3. Puig-Domingo M
    : Obesity and GLP-1. Minerva Endocrinol (Torino) 46(2): 168-176, 2021. PMID: 33213122. DOI: 10.23736/S2724-6507.20.03369-6
    OpenUrlCrossRefPubMed
  10. ↵
    1. Blonde L and
    2. Fonseca V
    : Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a comprehensive review of how to weigh the options, select the right patients, and maximize benefits. Endocr Pract, 2018. PMID: 30084684. DOI: 10.4158/EP-2018-0293
    OpenUrlCrossRefPubMed
  11. ↵
    1. Dharmalingam M,
    2. Sriram U and
    3. Baruah MP
    : Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab 15(1): 9-17, 2011. PMID: 21584160. DOI: 10.4103/2230-8210.77571
    OpenUrlCrossRefPubMed
  12. ↵
    1. Iorga RA,
    2. Bacalbasa N,
    3. Carsote M,
    4. Bratu OG,
    5. Stanescu AMA,
    6. Bungau S,
    7. Pantis C and
    8. Diaconu CC
    : Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med 20(3): 2396-2400, 2020. PMID: 32765722. DOI: 10.3892/etm.2020.8714
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ryan GJ,
    2. Foster KT and
    3. Jobe LJ
    : Review of the therapeutic uses of liraglutide. Clin Ther 33(7): 793-811, 2011. PMID: 21741090. DOI: 10.1016/j.clinthera.2011.06.004
    OpenUrlCrossRefPubMed
  14. ↵
    1. Attia SL,
    2. Softic S and
    3. Mouzaki M
    : Evolving role for pharmacotherapy in NAFLD/NASH. Clin Transl Sci 14(1): 11-19, 2021. PMID: 32583961. DOI: 10.1111/cts.12839
    OpenUrlCrossRefPubMed
    1. Ratziu V
    : Novel pharmacotherapy options for NASH. Dig Dis Sci 61(5): 1398-1405, 2016. PMID: 27003143. DOI: 10.1007/s10620-016-4128-z
    OpenUrlCrossRefPubMed
  16. ↵
    1. Cegla J
    : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study. Ann Clin Biochem 53(4): 518, 2016. PMID: 28071092. DOI: 10.1177/0004563216648250
    OpenUrlCrossRefPubMed
  17. ↵
    1. Zafar Y,
    2. Rashid AM,
    3. Siddiqi AK,
    4. Ellahi A,
    5. Ahmed A,
    6. Hussain HU,
    7. Ahmed F,
    8. Menezes RG,
    9. Siddiqi TJ and
    10. Maniya MT
    : Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 46(7): 101970, 2022. PMID: 35659603. DOI: 10.1016/j.clinre.2022.101970
    OpenUrlCrossRefPubMed
    1. Dai Y,
    2. He H,
    3. Li S,
    4. Yang L,
    5. Wang X,
    6. Liu Z and
    7. An Z
    : Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis. Front Endocrinol (Lausanne) 11: 622589, 2021. PMID: 33664710. DOI: 10.3389/fendo.2020.622589
    OpenUrlCrossRefPubMed
  19. ↵
    1. Fan S,
    2. Shi X,
    3. Yao J,
    4. Zhong M and
    5. Feng P
    : The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig 112(8): 627-635, 2020. PMID: 32496108. DOI: 10.17235/reed.2020.6392/2019
    OpenUrlCrossRefPubMed
  20. ↵
    1. Dong Y,
    2. Lv Q,
    3. Li S,
    4. Wu Y,
    5. Li L,
    6. Li J,
    7. Zhang F,
    8. Sun X and
    9. Tong N
    : Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 41(3): 284-295, 2017. PMID: 28065744. DOI: 10.1016/j.clinre.2016.11.009
    OpenUrlCrossRefPubMed
  21. ↵
    1. Alfaraidi H and
    2. Samaan MC
    : Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review. Front Endocrinol (Lausanne) 13: 1072879, 2023. PMID: 36814831. DOI: 10.3389/fendo.2022.1072879
    OpenUrlCrossRefPubMed
  22. ↵
    1. Damanhouri ZA,
    2. Alkreathy HM,
    3. Alharbi FA,
    4. Abualhamail H and
    5. Ahmad MS
    : A review of the impact of pharmacogenetics and metabolomics on the efficacy of metformin in type 2 diabetes. Int J Med Sci 20(1): 142-150, 2023. PMID: 36619226. DOI: 10.7150/ijms.77206
    OpenUrlCrossRefPubMed
  23. ↵
    1. Sturm N,
    2. Bronowicki JP,
    3. Maynard-Muet M,
    4. Tran A,
    5. Heluwaert F,
    6. Plages A and
    7. Zarski JP
    : Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. Gastroenterol Clin Biol 33(10-11): 984-986, 2009. PMID: 19646832. DOI: 10.1016/j.gcb.2009.05.010
    OpenUrlCrossRefPubMed
    1. Lujambio A and
    2. Sarobe P
    : Metformin keeps CD8(+) T cells active and moving in NASH-HCC immunotherapy. J Hepatol 77(3): 593-595, 2022. PMID: 35714813. DOI: 10.1016/j.jhep.2022.05.038
    OpenUrlCrossRefPubMed
  25. ↵
    1. Huang CF,
    2. Tiao MM,
    3. Lin IC,
    4. Huang LT,
    5. Sheen JM,
    6. Tain YL,
    7. Hsu CN,
    8. Tsai CC,
    9. Lin YJ and
    10. Yu HR
    : Maternal metformin treatment reprograms maternal high-fat diet-induced hepatic steatosis in offspring associated with placental glucose transporter modifications. Int J Mol Sci 23(22): 14239, 2022. PMID: 36430717. DOI: 10.3390/ijms232214239
    OpenUrlCrossRefPubMed
  26. ↵
    1. Tang W,
    2. Xu Q,
    3. Hong T,
    4. Tong G,
    5. Feng W,
    6. Shen S,
    7. Bi Y and
    8. Zhu D
    : Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev 32(2): 200-216, 2016. PMID: 26381272. DOI: 10.1002/dmrr.2713
    OpenUrlCrossRefPubMed
  27. ↵
    1. Li Y,
    2. Liu L,
    3. Wang B,
    4. Wang J and
    5. Chen D
    : Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 1(1): 57-64, 2013. PMID: 24648894. DOI: 10.3892/br.2012.18
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lavynenko O,
    2. Abdul-Ghani M,
    3. Alatrach M,
    4. Puckett C,
    5. Adams J,
    6. Abdelgani S,
    7. Alkhouri N,
    8. Triplitt C,
    9. Clarke GD,
    10. Vasquez JA,
    11. Li J,
    12. Cersosimo E,
    13. Gastaldelli A and
    14. DeFronzo RA
    : Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 24(5): 899-907, 2022. PMID: 35014145. DOI: 10.1111/dom.14650
    OpenUrlCrossRefPubMed
    1. Ozturk ZA and
    2. Kadayifci A
    : Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol 6(4): 199-206, 2014. PMID: 24799988. DOI: 10.4254/wjh.v6.i4.199
    OpenUrlCrossRefPubMed
    1. Marchesini G,
    2. Brizi M,
    3. Bianchi G,
    4. Tomassetti S,
    5. Zoli M and
    6. Melchionda N
    : Metformin in non-alcoholic steatohepatitis. Lancet 358(9285): 893-894, 2001. PMID: 11567710. DOI: 10.1016/s0140-6736(01)06042-1
    OpenUrlCrossRefPubMed
    1. Nair S,
    2. Diehl AM,
    3. Wiseman M,
    4. Farr GH Jr. and
    5. Perrillo RP
    : Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20(1): 23-28, 2004. PMID: 15225167. DOI: 10.1111/j.1365-2036.2004.02025.x
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schwimmer JB,
    2. Middleton MS,
    3. Deutsch R and
    4. Lavine JE
    : A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 21(7): 871-879, 2005. PMID: 15801922. DOI: 10.1111/j.1365-2036.2005.02420.x
    OpenUrlCrossRefPubMed
  33. ↵
    1. DA Silva Thomaz M,
    2. Ribeiro DA,
    3. Dos Santos JN and
    4. Nagaoka MR
    : Morphological changes in major salivary glands in mice treated with a choline and methionine deficient diet. In Vivo 36(5): 2243-2247, 2022. PMID: 36099116. DOI: 10.21873/invivo.12951
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Neri AA,
    2. Dontas IA,
    3. Iliopoulos DC and
    4. Karatzas T
    : Pathophysiological changes during ischemia-reperfusion injury in rodent hepatic steatosis. In Vivo 34(3): 953-964, 2020. PMID: 32354880. DOI: 10.21873/invivo.11863
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Review Team,
    2. LaBrecque DR,
    3. Abbas Z,
    4. Anania F,
    5. Ferenci P,
    6. Khan AG,
    7. Goh KL,
    8. Hamid SS,
    9. Isakov V,
    10. Lizarzabal M,
    11. Peñaranda MM,
    12. Ramos JF,
    13. Sarin S,
    14. Stimac D,
    15. Thomson AB,
    16. Umar M,
    17. Krabshuis J,
    18. LeMair A and World Gastroenterology Organisation
    : World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 48(6): 467-473, 2014. PMID: 24921212. DOI: 10.1097/MCG.0000000000000116
    OpenUrlCrossRefPubMed
  36. ↵
    1. Xie F,
    2. Zhong Y,
    3. Wang D,
    4. So KF,
    5. Xiao J and
    6. Lv Y
    : Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway. Mol Biol Rep 49(8): 7837-7848, 2022. PMID: 35733070. DOI: 10.1007/s11033-022-07610-y
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kuchay MS,
    2. Krishan S,
    3. Mishra SK,
    4. Choudhary NS,
    5. Singh MK,
    6. Wasir JS,
    7. Kaur P,
    8. Gill HK,
    9. Bano T,
    10. Farooqui KJ and
    11. Mithal A
    : Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11): 2434-2445, 2020. PMID: 32865597. DOI: 10.1007/s00125-020-05265-7
    OpenUrlCrossRefPubMed
  38. ↵
    1. Iogna Prat L and
    2. Tsochatzis EA
    : The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones (Athens) 17(2): 219-229, 2018. PMID: 29858843. DOI: 10.1007/s42000-018-0021-9
    OpenUrlCrossRefPubMed
  39. ↵
    1. Pinter M,
    2. Pinato DJ,
    3. Ramadori P and
    4. Heikenwalder M
    : NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin Cancer Res 29(3): 513-520, 2023. PMID: 36166660. DOI: 10.1158/1078-0432.CCR-21-1258
    OpenUrlCrossRefPubMed
  40. ↵
    1. Pal Chaudhary S,
    2. Reyes S,
    3. Chase ML,
    4. Govindan A,
    5. Zhao L,
    6. Luther J,
    7. Bhan I,
    8. Bethea E,
    9. Franses JW,
    10. Paige Walsh E,
    11. Anne Dageford L,
    12. Kimura S,
    13. Elias N,
    14. Yeh H,
    15. Markman J,
    16. Bozorgzadeh A,
    17. Tanabe K,
    18. Ferrone C,
    19. Zhu AX,
    20. Andersson K,
    21. Thiim M,
    22. Antonio Catalano O,
    23. Kambadakone A,
    24. Vagefi PA,
    25. Qadan M,
    26. Pratt D,
    27. Hashemi N,
    28. Corey KE,
    29. Misdraji J,
    30. Goyal L and
    31. Clark JW
    : Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): Clinical features and outcomes compared with HCC due to other etiologies. Oncologist: oyac251, 2023. PMID: 36763374. DOI: 10.1093/oncolo/oyac251
    OpenUrlCrossRefPubMed
  41. ↵
    1. Yu Z,
    2. Wu Y,
    3. Zhang R,
    4. Li Y,
    5. Zang S and
    6. Liu J
    : Increased risk of non-alcoholic fatty liver disease fibrosis is closely associated with osteoporosis in women but not in men with type 2 diabetes. Endocr Connect 11(11): e220174, 2022. PMID: 36129166. DOI: 10.1530/EC-22-0174
    OpenUrlCrossRefPubMed
  42. ↵
    1. Bañares J,
    2. Manzano-Nuñez R,
    3. Prió A,
    4. Rivera-Esteban J,
    5. Camps-Relats L,
    6. Villarejo A,
    7. Ruiz-Ortega L,
    8. Pons M,
    9. Ciudin A,
    10. Salcedo MT,
    11. Vargas V,
    12. Genescà J and
    13. Pericàs JM
    : Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study. Front Endocrinol (Lausanne) 13: 945626, 2022. PMID: 36093073. DOI: 10.3389/fendo.2022.945626
    OpenUrlCrossRefPubMed
  43. ↵
    1. Tacelli M,
    2. Celsa C,
    3. Magro B,
    4. Giannetti A,
    5. Pennisi G,
    6. Spatola F and
    7. Petta S
    : Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? Pharmaceuticals (Basel) 11(4): 121, 2018. PMID: 30413050. DOI: 10.3390/ph11040121
    OpenUrlCrossRefPubMed
    1. Mahjoubin-Tehran M,
    2. De Vincentis A,
    3. Mikhailidis DP,
    4. Atkin SL,
    5. Mantzoros CS,
    6. Jamialahmadi T and
    7. Sahebkar A
    : Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab 50: 101049, 2021. PMID: 32673798. DOI: 10.1016/j.molmet.2020.101049
    OpenUrlCrossRefPubMed
    1. Mantovani A,
    2. Byrne CD,
    3. Scorletti E,
    4. Mantzoros CS and
    5. Targher G
    : Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab 46(6): 427-441, 2020. PMID: 31923578. DOI: 10.1016/j.diabet.2019.12.007
    OpenUrlCrossRefPubMed
    1. Tian F,
    2. Zheng Z,
    3. Zhang D,
    4. He S and
    5. Shen J
    : Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep 38(6): , 2018. PMID: 30473540. DOI: 10.1042/BSR20181304
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Yan J,
    2. Yao B,
    3. Kuang H,
    4. Yang X,
    5. Huang Q,
    6. Hong T,
    7. Li Y,
    8. Dou J,
    9. Yang W,
    10. Qin G,
    11. Yuan H,
    12. Xiao X,
    13. Luo S,
    14. Shan Z,
    15. Deng H,
    16. Tan Y,
    17. Xu F,
    18. Xu W,
    19. Zeng L,
    20. Kang Z and
    21. Weng J
    : Liraglutide, sitagliptin, and insulin glargine added to metformin: The effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 69(6): 2414-2426, 2019. PMID: 30341767. DOI: 10.1002/hep.30320
    OpenUrlCrossRefPubMed
  48. ↵
    1. Ji J,
    2. Feng M,
    3. Huang Y and
    4. Niu X
    : Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 13(3): 5091-5102, 2022. PMID: 35164657. DOI: 10.1080/21655979.2022.2036902
    OpenUrlCrossRefPubMed
  49. ↵
    1. Zhang Q,
    2. Liu Q and
    3. Niu CY
    : [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver]. Zhonghua Gan Zang Bing Za Zhi 29(5): 456-461, 2021. PMID: 34107584. DOI: 10.3760/cma.j.cn501113-20200427-00219
    OpenUrlCrossRefPubMed
  50. ↵
    1. Fang Y,
    2. Ji L,
    3. Zhu C,
    4. Xiao Y,
    5. Zhang J,
    6. Lu J,
    7. Yin J and
    8. Wei L
    : Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front Cell Dev Biol 8: 602574, 2020. PMID: 33330497. DOI: 10.3389/fcell.2020.602574
    OpenUrlCrossRefPubMed
  51. ↵
    1. Ao N,
    2. Ma Z,
    3. Yang J,
    4. Jin S,
    5. Zhang K,
    6. Luo E and
    7. Du J
    : Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway. Peptides 133: 170375, 2020. PMID: 32771373. DOI: 10.1016/j.peptides.2020.170375
    OpenUrlCrossRefPubMed
  52. ↵
    1. Baandrup Kristiansen MN,
    2. Veidal SS,
    3. Christoffersen C,
    4. Feigh M,
    5. Vrang N,
    6. Roth JD,
    7. Erickson M,
    8. Adorini L and
    9. Jelsing J
    : Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterol 19(1): 228, 2019. PMID: 31883514. DOI: 10.1186/s12876-019-1149-z
    OpenUrlCrossRefPubMed
  53. ↵
    1. Zhou R,
    2. Lin C,
    3. Cheng Y,
    4. Zhuo X,
    5. Li Q,
    6. Xu W,
    7. Zhao L and
    8. Yang L
    : Liraglutide alleviates hepatic steatosis and liver injury in T2MD rats via a GLP-1R dependent AMPK pathway. Front Pharmacol 11: 600175, 2021. PMID: 33746742. DOI: 10.3389/fphar.2020.600175
    OpenUrlCrossRefPubMed
  54. ↵
    1. Zhang L,
    2. Li HX,
    3. Pan WS,
    4. Ullah Khan F,
    5. Qian C,
    6. Qi-Li FR and
    7. Xu X
    : Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-α. Biomed Pharmacother 111: 99-108, 2019. PMID: 30579258. DOI: 10.1016/j.biopha.2018.12.059
    OpenUrlCrossRefPubMed
  55. ↵
    1. Cichocki JA,
    2. Furuya S,
    3. Konganti K,
    4. Luo YS,
    5. McDonald TJ,
    6. Iwata Y,
    7. Chiu WA,
    8. Threadgill DW,
    9. Pogribny IP and
    10. Rusyn I
    : Impact of nonalcoholic fatty liver disease on toxicokinetics of tetrachloroethylene in mice. J Pharmacol Exp Ther 361(1): 17-28, 2017. PMID: 28148637. DOI: 10.1124/jpet.116.238790
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Wang SW,
    2. Lan T,
    3. Sheng H,
    4. Zheng F,
    5. Lei MK,
    6. Wang LX,
    7. Chen HF,
    8. Xu CY and
    9. Zhang F
    : Nobiletin alleviates non-alcoholic steatohepatitis in MCD-induced mice by regulating macrophage polarization. Front Physiol 12: 687744, 2021. PMID: 34093242. DOI: 10.3389/fphys.2021.687744
    OpenUrlCrossRefPubMed
    1. Che Y,
    2. Shi X,
    3. Zhong X,
    4. Zhang Y,
    5. Si R,
    6. Li Y and
    7. Shi Y
    : Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. J Nutr Biochem 82: 108400, 2020. PMID: 32438122. DOI: 10.1016/j.jnutbio.2020.108400
    OpenUrlCrossRefPubMed
  58. ↵
    1. Ji G,
    2. Wang Y,
    3. Deng Y,
    4. Li X and
    5. Jiang Z
    : Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis 14: 134, 2015. PMID: 26498332. DOI: 10.1186/s12944-015-0139-6
    OpenUrlCrossRefPubMed
  59. ↵
    1. Chen Y,
    2. Xu YN,
    3. Ye CY,
    4. Feng WB,
    5. Zhou QT,
    6. Yang DH and
    7. Wang MW
    : GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacol Sin 43(5): 1156-1166, 2022. PMID: 34934197. DOI: 10.1038/s41401-021-00836-9
    OpenUrlCrossRefPubMed
  60. ↵
    1. Matikainen N,
    2. Söderlund S,
    3. Björnson E,
    4. Pietiläinen K,
    5. Hakkarainen A,
    6. Lundbom N,
    7. Taskinen MR and
    8. Borén J
    : Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab 21(1): 84-94, 2019. PMID: 30073766. DOI: 10.1111/dom.13487
    OpenUrlCrossRefPubMed
    1. Decara J,
    2. Rivera P,
    3. Arrabal S,
    4. Vargas A,
    5. Serrano A,
    6. Pavón FJ,
    7. Dieguez C,
    8. Nogueiras R,
    9. Rodríguez de Fonseca F and
    10. Suárez J
    : Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats. Acta Physiol (Oxf) 222(4): e13008, 2018. PMID: 29193738. DOI: 10.1111/apha.13008
    OpenUrlCrossRefPubMed
  62. ↵
    1. More VR,
    2. Lao J,
    3. McLaren DG,
    4. Cumiskey AM,
    5. Murphy BA,
    6. Chen Y,
    7. Previs S,
    8. Stout S,
    9. Patel R,
    10. Satapati S,
    11. Li W,
    12. Kowalik E,
    13. Szeto D,
    14. Nawrocki A,
    15. Pocai A,
    16. Wang L and
    17. Carrington P
    : Glucagon like receptor 1/glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. PLoS One 12(10): e0186586, 2017. PMID: 29065174. DOI: 10.1371/journal.pone.0186586
    OpenUrlCrossRefPubMed
  63. ↵
    1. Zhang A,
    2. Qian F,
    3. Li Y,
    4. Li B,
    5. Yang F,
    6. Hu C,
    7. Sun W and
    8. Huang Y
    : Research progress of metformin in the treatment of liver fibrosis. Int Immunopharmacol 116: 109738, 2023. PMID: 36696857. DOI: 10.1016/j.intimp.2023.109738
    OpenUrlCrossRefPubMed
  64. ↵
    1. Du Y,
    2. Zhu YJ,
    3. Zhou YX,
    4. Ding J and
    5. Liu JY
    : Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study. Mol Biomed 3(1): 41, 2022. PMID: 36484892. DOI: 10.1186/s43556-022-00108-w
    OpenUrlCrossRefPubMed
  65. ↵
    1. Zhang Y,
    2. Wang H and
    3. Xiao H
    : Metformin actions on the liver: Protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC. Int J Mol Sci 22(9): 5016, 2021. PMID: 34065108. DOI: 10.3390/ijms22095016
    OpenUrlCrossRefPubMed
    1. Zheng J,
    2. Woo SL,
    3. Hu X,
    4. Botchlett R,
    5. Chen L,
    6. Huo Y and
    7. Wu C
    : Metformin and metabolic diseases: a focus on hepatic aspects. Front Med 9(2): 173-186, 2015. PMID: 25676019. DOI: 10.1007/s11684-015-0384-0
    OpenUrlCrossRefPubMed
  67. ↵
    1. Rouabhia S,
    2. Milic N and
    3. Abenavoli L
    : Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol 8(4): 343-349, 2014. PMID: 24580044. DOI: 10.1586/17474124.2014.894880
    OpenUrlCrossRefPubMed
  68. ↵
    1. Li YL,
    2. Li XQ,
    3. Wang YD,
    4. Shen C and
    5. Zhao CY
    : Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. Biochem Biophys Res Commun 513(1): 64-72, 2019. PMID: 30935688. DOI: 10.1016/j.bbrc.2019.03.077
    OpenUrlCrossRefPubMed
  69. ↵
    1. Yang JS,
    2. Lu CC,
    3. Kuo SC,
    4. Hsu YM,
    5. Tsai SC,
    6. Chen SY,
    7. Chen YT,
    8. Lin YJ,
    9. Huang YC,
    10. Chen CJ,
    11. Lin WD,
    12. Liao WL,
    13. Lin WY,
    14. Liu YH,
    15. Sheu JC and
    16. Tsai FJ
    : Autophagy and its link to type II diabetes mellitus. Biomedicine (Taipei) 7(2): 8, 2017. PMID: 28612706. DOI: 10.1051/bmdcn/2017070201
    OpenUrlCrossRefPubMed
  70. ↵
    1. Zhang D,
    2. Ma Y,
    3. Liu J,
    4. Deng Y,
    5. Zhou B,
    6. Wen Y,
    7. Li M,
    8. Wen D,
    9. Ying Y,
    10. Luo S,
    11. Shi C,
    12. Pu G,
    13. Miao Y,
    14. Zou C,
    15. Chen Y and
    16. Ma L
    : Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor EB-dependent autophagy. Front Pharmacol 12: 689111, 2021. PMID: 34366846. DOI: 10.3389/fphar.2021.689111
    OpenUrlCrossRefPubMed
  71. ↵
    1. Tsai SC,
    2. Yang JS,
    3. Lu CC,
    4. Tsai FJ,
    5. Chiu YJ and
    6. Kuo SC
    : MTH-3 sensitizes oral cancer cells to cisplatin via regulating TFEB. J Pharm Pharmacol 74(9): 1261-1273, 2022. PMID: 35880728. DOI: 10.1093/jpp/rgac056
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
HONG-YI CHIU, SHIH-CHANG TSAI, FUU-JEN TSAI, YU-HSIANG LO, CHING-CHANG CHENG, TING-YUAN LIU, SYUN-RONG JHAN, JAI-SING YANG, YU-JEN CHIU
In Vivo May 2023, 37 (3) 1037-1046; DOI: 10.21873/invivo.13178
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords